Glucagon like peptide-1 (GLP-1) Elastin like peptide (ELP)-120 fusion protein

Glucagon like peptide-1 (GLP-1) Elastin like peptide (ELP)-120 fusion protein

ImmunoForge Co., Ltd.

2021

—

Designated

(2S,3R)-N-[(2S)-3-(cyclopent-1-en-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[(2S)-2-[2-(morpholin-4-yl)acetamido]propanamido]propanamide maleate

(2S,3R)-N-[(2S)-3-(cyclopent-1-en-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[(2S)-2-[2-(morpholin-4-yl)acetamido]propanamido]propanamide maleate

Kezar Life Sciences, Inc.

2020

—

Designated

Siponimod

Siponimod

Novartis Pharmaceuticals Corporation

2013

—

Withdrawn

[NCT06455449](https://clinicaltrials.gov/study/NCT06455449)

A Study to Investigate the Efficacy and Safety of Anifrolumab Administered as Subcutaneous Injection and Added to Standard of Care Compared With Placebo Added to Standard of Care in Adult Participants With Idiopathic Inflammatory Myopathies (Polymyositis and Dermatomyositis)

PHASE3

AstraZeneca

RECRUITING

[NCT07160205](https://clinicaltrials.gov/study/NCT07160205)

Safety and Efficacy of ULSC on Disease Severity and Steroid Tapering in Participants With Dermatomyositis/ Polymyositis (DM/PM), Also Known as Idiopathic Inflammatory Myopathy (IIM)

PHASE2

Restem, LLC.

RECRUITING

[NCT06154252](https://clinicaltrials.gov/study/NCT06154252)

RESET-Myositis: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Idiopathic Inflammatory Myopathy or Juvenile Idiopathic Inflammatory Myopathy

PHASE2

Cabaletta Bio

RECRUITING

[NCT01276470](https://clinicaltrials.gov/study/NCT01276470)

Environmental Risk Factors for the Anti-synthetase Syndrome

—

National Institute of Environmental Health Sciences (NIEHS)

RECRUITING